Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Uric acid as a risk factor for cardiovascular disease and mortality
Session:
Posters (Sessão 4 - Écran 5) - Risco Cardiovascular 2
Speaker:
M. Raquel Santos
Congress:
CPC 2022
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.7 Diabetes and the Heart
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
m. Raquel Santos; Maria Isabel Mendonça; Margarida Temtem; Débora sá; Ana Célia Sousa; Sónia Freitas; Eva Henriques; Mariana Rodrigues; Sofia Borges; Ilídio Ornelas; António Drumond; Roberto Palma Dos Reis
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman","serif""><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif"">Introduction: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""><span style="color:#333333">Several studies show a central role for high uric acid (UA) levels in several conditions as diabetes, hypertension, dyslipidemia, kidney failure, coronary artery disease (CAD), and cardiovascular (CV) mortality.</span></span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""> <span style="color:#333333">Most guidelines recommend treating symptomatic patients even with a stabilized plasmatic level of ≤6 mg/dL. Treatment of asymptomatic patients remains hotly debated.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong>Objective</strong>: To estimate whether high UA levels were an independent risk factor to CAD in general or within specific sub-groups: diabetes, hypertension, dyslipidemia and kidney failure and to evaluate their association with CV mortality at the follow-up.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong>Materials and methods</strong>: We performed a case-control study with 3160 participants (1723 patients and 1437 controls), evaluating whether the UA levels (> median) were a risk factor to CAD as well as to the specific sub-groups diabetes, hypertension, dyslipidemia and kidney failure, using bivariate and multivariate analyses. After, we managed a prospective study with 1723 coronary patients followed a mean of 4.9±3.4 years. Using Cox analysis, we estimated whether the UA high levels were a risk factor for CAD and CVD mortality and assessed the statistical difference in survival for two UA groups (above and below the median) with the Kaplan-Meier survival analysis<span style="background-color:white"><span style="color:black">.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,"sans-serif""><strong><span style="background-color:white"><span style="color:black">Results:</span></span></strong><span style="background-color:white"><span style="color:black"> The median value was 6.01 mg/dL, and values above the median were considered as having hyperuricemia. Although there was a significant predisposition for CAD with values >6mg/dL in bivariate analyses, this was not maintained after multivariate analysis, except in the diabetic subgroup. </span></span><span style="background-color:white"><span style="color:black">In the Cox analyze, the UA >6.01 had a hazard ratio (HR) of 1.4 (p=0.020) for CV mortality and 1.9 (p<0.0001) for diabetes. Kaplan Meier showed that patients below the median had better survival at the follow-up end (p=0.008).</span></span></span></span></p> <p><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif"">Conclusions:</span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri","sans-serif""> High UA levels were an independent predictor of cardiovascular mortality in our work. This risk factor showed independent CAD risk only in diabetic patients. This point may allow identifying patient’s sets that are likely to benefit from long-term uric acid-lowering therapies.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site